Enoxaparin (a low molecular weight heparin) has been used extensively for its antithrombotic properties. Complications of its haemorrhagic side-effects have previously been described. We report two cases of extensive retroperitoneal haematoma requiring blood transfusion and inotropic support. One patient developed acute renal failure and did not respond to intensive resuscitative efforts.
Enoxaparin (a low molecular weight heparin) has been used extensively for its antithrombotic action. The indications for usage include deep venous thrombosis prophylaxis and acute coronary syndromes. It is also indicated for usage in the treatment of deep venous thrombosis and is being investigated for the treatment of pulmonary embolism.
Enoxaparin has prolonged antithrombotic properties at recommended dosages without any significant change in global blood clotting tests. It is best monitored by measuring changes in plasma anti-Xa activity. Complications have been described relating to the bleeding side-effects of enoxaparin, however there are very few reports relating to retroperitoneal haematomas with enoxaparin and we report two such cases.
CASE REPORT
A 76-year-old female patient was admitted to the Coronary Care Unit with new onset, recurrent collapses (without loss of consciousness). On examination she was found to be in rapid atrial fibrillation with a heart rate of 180/min and diffuse ST segment changes on the electrocardiogram, but the troponin I levels were normal. She was managed with amio-darone (5 mg/kg intravenous bolus followed by an infusion of 10 mg/kg/day) which successfully reversed the arrhythmia after a few hours. She was also anticoagulated with enoxaparin 60 mg 12 hourly subcutaneously. Her body mass was 70 kg. Two days later after four doses of enoxaparin, she developed a large rectus sheath haematoma, became anuric and her haemoglobin fell to a level of 78 g/l from 137 g/l on admission. Her clotting profile checked nine hours after the first dose of enoxaparin showed INR 1.0, PT 12 s, aPTT 45 s, fibrinogen 2.2 g/l, platelets 160 x10 9 /l. There were no subsequent significant changes in these values during the course of her admission. The initial management was with intravenous fluids (saline 0.9% one litre initially followed by 120 ml/h) and two doses of frusemide 20 mg intravenously. With no response a dopamine infusion at a rate of 2.5 µg/kg/min was started.
She was then transferred to the Intensive Care Unit and was haemodynamically stable but had a clinically obvious rectus sheath swelling/haematoma. A CT scan of the abdomen showed a bilateral rectus sheath haematoma and a large, retroperitoneal pelvic haematoma. The dimensions were not defined because of the irregular structure of the haematoma. It was not seen to be compressing the urinary collecting system.
The ongoing management consisted of blood transfusion of eight units of packed cells (in total) and diuretic infusion (frusemide 10 mg/h). Over the subsequent five days the acute renal failure resolved and the haematoma settled without surgical exploration. Prophylactic antibiotics were not prescribed. Due to the bleeding complications incurred and the fact that the atrial fibrillation had been successfully treated, no further anticoagulants were used.
CASE HISTORY 2
An 80-year-old male patient was transferred from a peripheral hospital to the medical unit with a six-day history of chest pain. The patient had an extensive past medical history including ischaemic heart disease, hypertension, type II diabetes, chronic renal failure, asthma, temporal arteritis and previous cerebrovascular accident. His regular medication included aspirin, irbesartan, frusemide, diltiazem, digoxin, prednisolone and atorvastatin.
He had been referred for cardiological workup but had refused angiography and opted to continue with medical management of his angina.
On arrival he was suffering from ongoing chest pain. He was haemodynamically stable. The electrocardiogram showed a right bundle branch block but no other evidence of ischaemic changes. Biochemistry showed a rise in troponin levels (TNI 1.3 µg/l). He also had deteriorating renal function with a urea of 22.5 mmol/l and serum creatinine of 0.26 mmol/l. His clotting profile was at this stage normal. As part of his management, enoxaparin 100 mg 12 hourly subcutaneously had been started before referral and this was continued. The anticoagulant effect of the enoxaparin was not monitored as the test for anti-Xa is not available in the local regional laboratory. His body weight was 100 kg. His chest pain continued and morphine was also used intermittently.
Nine days after admission a single dose of indomethacin 100 mg PR was administered rectally for ongoing chest pain. On day ten the Medical Emergency Team was called and he was found to be profoundly anaemic and had a distended abdomen. He was transferred to the Intensive Care Unit where he required intubation, ventilation and cardiopulmonary resuscitation. After stabilization he was taken for a CT scan of the abdomen and this revealed a large, left-sided, retroperitoneal haematoma. The aorta appeared normal.
The laboratory results showed Hb 92 g/l, platelets 248x10 9 /l, INR 1.6, PT 17 s, aPTT 54 s and fibrinogen 3.2 g/l. He failed to respond to therapy and died the following day.
DISCUSSION
Low molecular weight heparins (LMWH) have entered widespread use in the last decade and are now the preferred agents over unfractionated heparin (UFH) for prophylaxis and management of deep vein thrombosis (DVT) and the management of acute coronary syndromes. LMWHs are also being investigated for the management of pulmonary embolism and for anticoagulant support during interventional cardiological procedures 1 .
There are three available LMWHs and these are enoxaparin, dalteparin and nadroparin. Enoxaparin has the highest level of specificity for its action on anti-Xa and the ratio of anti-Xa/IIa activity is 3.8:1. After subcutaneous administration enoxaparin is rapidly and completely absorbed with a bioavailability of 90%. The elimination half-life is 4.4 hours for a dose of 40 mg, although circulating levels of anti-Xa are present in the plasma 24 hours after injection. Breakdown of enoxaparin takes place mainly in the liver and small amounts of the product are eliminated in the kidney. Elimination of enoxaparin at prophylactic dosages is not significantly modified in patients with renal insufficiency and research done on patients with end-stage renal disease has shown that based on anti-Xa activity, the pharmacokinetics are largely unchanged and dosing adjustments are unnecessary 10 . However a retrospective chart review examining patients, with and without renal insufficiency, who had more than two doses of enoxaparin, showed increased bleeding complications in the latter group 11 . The dosage recommendations for enoxaparin are 40 mg once daily for three weeks for prophylaxis against thromboembolism and 1 mg/kg 12 hourly for two to eight days in the management of acute coronary syndromes.
The haemorrhagic complications related to the use of UFH and oral anticoagulants have been extensively reviewed . In respect of LMWHs there has been extensive discussion about the risks of haemorrhage relating to the concomitant performance of major neuraxial blocks 3, 4 .
However the risk of spontaneous retroperitoneal haematoma following the use of enoxaparin has not been widely reported. A review of the literature (Medline) from 1966 to October 2001 revealed one letter to the editor reporting such a case 5 . There is also a report of two patients developing large abdominal wall haematomas after receiving enoxaparin for prophylaxis against DVT 6 .
In both these patients the enoxaparin was being used in the recommended dose of 1 mg/kg. There was no previous indication that the patients had any clotting abnormalities. The second patient was however on aspirin and prior to the development of the haematoma was administered a dose of indomethacin. The synergism between aspirin and enoxaparin has been described 7 . However aspirin is recommended to be used in combination with enoxaparin in the treatment of acute coronary syndromes 1 . Other sites of haemorrhage that have been described include an intrahepatic haemorrhage 8 and a psoas haematoma following lumbar plexus block 9 .
In these instances of haemorrhage, the use of protamine may be considered and it has been recommended in MIMS Australia for enoxaparin overdosage. However protamine has no effect on anti-Xa activity and there is no research relating to the use thereof in the management of such bleeding complications.
These two patients presented in close temporal proximity to each other and it raised the question of whether such bleeding complications occur more commonly but remain clinically unrecognized. This may suggest that further work needs to be done in searching for these complications. However, more directly it reinforces the need to remain aware of the bleeding complications of anticoagulant drugs and in the event of haemodynamic instability or changing haematologic profiles, a careful search for a source of bleeding has to be undertaken.
